港股午评|恒生指数早盘跌0.18% 生物医药板块强势

Group 1: Market Overview - The Hang Seng Index fell by 0.18%, down 41 points, closing at 23,241 points, while the Hang Seng Tech Index decreased by 0.58% [1] - Early trading volume in Hong Kong stocks reached HKD 111.4 billion [1] Group 2: Pharmaceutical Sector - Pharmaceutical stocks showed strength in early trading, driven by significant data expected to be released at the ASCO conference, enhancing the industry's outlook for innovative drugs [1] - Junshi Biosciences (01877) rose by 6%, Lepu Biopharma-B (02157) increased by 8%, King’s Ray Biotech (01548) gained 5%, and WuXi AppTec (02268) also saw a 5% rise [1] - Heyu-B (02256) surged over 2% after receiving CDE approval for the breakthrough therapy designation for Ipagufin in treating HCC [1] - Yiming Oncology-B (01541) increased by over 4%, with results from the IMM2510/AXN-2510 combination chemotherapy Phase II trial expected to be announced in the second half of the year [1] Group 3: Technology and Other Sectors - ZhongAn Online (06060) rose over 5%, with a cumulative increase of over 30% in stock price this month, likely benefiting from the Hong Kong stablecoin bill [2] - Smoore International (06969) increased by over 7%, with the new generation of heat-not-burn product Glo Hilo set to launch in Japan [3] - Inspur Digital Enterprise (00596) rose over 7%, recognized as a leading company in China's ERP sector, with institutions noting its valuation is significantly undervalued compared to peers [3] - Gu Ming (01364) surged over 7% to reach a new high, with expectations to enter the Hong Kong Stock Connect next month and notable same-store sales growth in Q1 [4] - KEEP (03650) increased by over 7%, with the upcoming launch of a smart sports watch featuring upgraded AI running coach functions [4] - Jacobson Pharmaceutical (02633) rose over 5%, with projected net profit growth of over 10% year-on-year for the fiscal year 2025 [5] - Horizon Robotics-W (09660) increased by 9%, as the company was included in the Shenzhen-Hong Kong Stock Connect, with institutions expecting chip shipments to grow annually [5] - Giant Bio (02367) fell over 2% due to its brand Kefu Mei being involved in a "fake product" scandal, raising concerns from Citigroup about its performance during the 618 promotional period [5]